Global data from real world use of flash glucose monitoring have correlated higher frequency of scanning with better glycemic control. Because flash glucose monitoring became available in late 2017 in the United States, U.S. data was not captured in the early global flash glucose monitoring analysis. The objective of this study was highlight real world outcomes in patients using flash glucose monitoring in the U.S.
A server collected deidentified data from patients who uploaded their flash glucose monitoring system readers. Data from patients within the U.S. were analyzed through September 2018. Individuals were divided into 10 equal sized groups based on scanning frequency. Average time in range (70- 180 mg/dL) and time above range 180 mg/dL was calculated for each group.
This analysis includes 21,853 readers, 115,221 sensors, and 102 million glucose values with an average of 9 scans per day. Patients in the lowest scanning frequency decile (3.4 scans per day) had 55% time in range and 41% time above. Patients in the highest scanning frequency decile (30.7 scans per day) had 74% time in range and 21% time above. This represents a 49% reduction in the time above target and a 34% increase in the time in range.
Real world data from U.S. shows how frequency of scanning correlates with time in range and hyperglycemia. This analysis is consistent with prior analyses concluding that patients with diabetes who monitor their glucose more frequently derive greater benefit than patients who monitor less frequently.
E. Wright: Advisory Panel; Self; Abbott, Sanofi US, Voluntis USA. Consultant; Self; Abbott, Boehringer Ingelheim Pharmaceuticals, Inc. Speaker's Bureau; Self; Eli Lilly and Company. Other Relationship; Self; American Diabetes Association, Medscape, UpToDate. N. Virdi: Employee; Self; Abbott, Proteus Digital Health. Stock/Shareholder; Self; Johnson & Johnson. T. Dunn: Employee; Self; Abbott Laboratories.